<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Gastroenterol Res Pract</journal-id><journal-id journal-id-type="iso-abbrev">Gastroenterol Res Pract</journal-id><journal-id journal-id-type="publisher-id">GRP</journal-id><journal-title-group><journal-title>Gastroenterology Research and Practice</journal-title></journal-title-group><issn pub-type="ppub">1687-6121</issn><issn pub-type="epub">1687-630X</issn><publisher><publisher-name>Hindawi</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6854910</article-id><article-id pub-id-type="doi">10.1155/2019/8974751</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>The Challenge of Treatment in Potential Celiac Disease</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3869-1815</contrib-id><name><surname>Trovato</surname><given-names>Chiara Maria</given-names></name><email>chiaramariatrovato@gmail.com</email><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Montuori</surname><given-names>Monica</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1473-2240</contrib-id><name><surname>Valitutti</surname><given-names>Francesco</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Leter</surname><given-names>Beatrice</given-names></name><xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Cucchiara</surname><given-names>Salvatore</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2348-2308</contrib-id><name><surname>Oliva</surname><given-names>Salvatore</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="I1">
<sup>1</sup>Pediatric Gastroenterology and Liver Unit, Department of Pediatrics, Sapienza University of Rome, Rome, Italy</aff><aff id="I2">
<sup>2</sup>European Biomedical Research Institute of Salerno, Salerno, Italy</aff><aff id="I3">
<sup>3</sup>Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy</aff><author-notes><fn fn-type="other"><p>Academic Editor: Amosy M'Koma</p></fn></author-notes><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>20</day><month>10</month><year>2019</year></pub-date><volume>2019</volume><elocation-id>8974751</elocation-id><history><date date-type="received"><day>28</day><month>5</month><year>2019</year></date><date date-type="accepted"><day>19</day><month>8</month><year>2019</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2019 Chiara Maria Trovato et al.</copyright-statement><copyright-year>2019</copyright-year><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>Potential celiac disease (PCD) is defined by the presence of positive serum antibodies, HLA-DQ2/DQ8 haplotypes, and a normal small intestinal mucosa (Marsh grade 0-1). This condition occurs in one-fifth of celiac disease (CD) patients and usually represents a clinical challenge. We reviewed genetic, histologic, and clinical features of this specific condition by performing a systematic search on MEDLINE, Embase, and Scholar database. Accordingly, we identified different genetic features in patients with PCD compared to the classical forms. Frequently, signs of inflammation (deposits of immunoglobulin A (IgA) and/or increased number of intraepithelial lymphocytes) can be clearly identify in the mucosa of PCD patients after an accurate histological assessment. Finally, the main challenge is represented by the treatment: the gluten-free diet should be considered only in the presence of gluten-dependent symptoms in both children and adults. <italic>What is known</italic>: (i) potential celiac disease (PCD) occurs in one-fifth of all celiac diseases (CD), and (ii) despite the absence of classical lesions, clear signs of inflammation are often detectable. <italic>What is new</italic>: (i) patients with PCD show different genetic features, and (ii) the presence of gluten-dependent symptoms is the main determinant to initiate the gluten-free diet, after a complete diagnostic work-up.</p></abstract></article-meta></front><body><sec id="sec1"><title>1. Potential Celiac Disease</title><p>Celiac disease (CD) is a systemic disorder caused by gluten and characterized by the presence of a variable combination of gluten-dependent clinical manifestations, CD-specific antibodies, HLA-DQ2 or HLA-DQ8 haplotypes, and enteropathy [<xref rid="B1" ref-type="bibr">1</xref>]. Potential CD (PCD) is the condition related to people with a normal (Marsh grade 0) or minimally abnormal (Marsh grade 1) intestinal mucosa who are at increased risk of developing CD, as indicated by both positive serum endomysial (EmA) and tissue transglutaminase antibodies (tTGA2) and a positive histocompatibility leukocyte antigen (HLA-DQ2 or HLA-DQ8) genotype [<xref rid="B2" ref-type="bibr">2</xref>]. Symptoms and signs of the disease are not always clinically manifest, and even when present, they can range from mild to severe.</p><p>The term &#x0201c;potential CD&#x0201d; was first introduced by Ferguson in 1993 [<xref rid="B3" ref-type="bibr">3</xref>], and it has long been used interchangeably with &#x0201c;latent CD&#x0201d;; however, the latter has recently been discontinued, as suggested by the Oslo definition [<xref rid="B2" ref-type="bibr">2</xref>]. The diagnosis of PCD has significantly increased in the last years as a result of increased CD screening in the general population [<xref rid="B4" ref-type="bibr">4</xref>&#x02013;<xref rid="B6" ref-type="bibr">6</xref>]. The number of patients with PCD is now sizeable, and this condition represents about one-fifth of total CD patients [<xref rid="B7" ref-type="bibr">7</xref>]. Compared with active classical CD, PCD is characterized by features including lower prevalence of DQ2 and higher prevalence of DQ8 [<xref rid="B8" ref-type="bibr">8</xref>]. Patients with PCD more frequently show low-to-moderate HLA-related risk; these cases bear half of the DQ2 heterodimer, either DQB1<sup>&#x02217;</sup>02 or DQA1<sup>&#x02217;</sup>05 only. Furthermore, six polymorphisms have been differently distributed in potential CD; these factors could be implicated with CD pathogenesis maybe with a &#x0201c;gene-dosage&#x0201d; effect as reported for HLA [<xref rid="B9" ref-type="bibr">9</xref>]. Establishing a certain diagnosis of PCD is of the utmost importance. False positive values of antibodies can be determined by analytical or random errors in the assay. Conversely, negative histological findings can be generated by a small number of biopsies due to &#x0201c;patchy&#x0201d; involvement of the bulb and duodenal mucosa [<xref rid="B10" ref-type="bibr">10</xref>&#x02013;<xref rid="B13" ref-type="bibr">13</xref>], inappropriate biopsy orientation, the lack of the pathologists' expertise [<xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B15" ref-type="bibr">15</xref>], and an inadequate gluten intake before the endoscopy [<xref rid="B16" ref-type="bibr">16</xref>].</p></sec><sec id="sec2"><title>2. Histology Features and Prognostic Biomarkers</title><p>In PCD, despite the absence of severe mucosal damages, clear signs of inflammation are often present. There is a remarkable research activity to improve the diagnosis and identify initial mucosal changes in PCD: the four most important prognostic factors for villous atrophy are described in <xref ref-type="fig" rid="fig1">Figure 1</xref>. A short history of the most important findings concerning PCD is reported in <xref rid="tab1" ref-type="table">Table 1</xref>, and results from these studies are here described more in detail.</p><p>Paparo et al., in 2005, showed immunohistochemical features of immune activation in the epithelium, lamina propria, and crypts in PCD: 70.8% of PCD patients presented an increased number of lamina propria CD25+ and/or enhanced expression of ICAM-1 and crypt HLA-DR [<xref rid="B17" ref-type="bibr">17</xref>]. It has been hypothesized that circulating antitissue transglutaminase 2 (tTGA2) may be the result of a &#x0201c;spillover&#x0201d; from the intestinal mucosal layer [<xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B19" ref-type="bibr">19</xref>]. Therefore, identifying anti-tTGA2 deposits in the mucosal layer can be a key factor in the histological assessment of CD: such deposits have been reported below the epithelial layer and around blood vessels in both pediatric and adult patients with overt CD [<xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B21" ref-type="bibr">21</xref>]. These features could also have a predictive role for villous atrophy, since they have been described in early-stage CD [<xref rid="B22" ref-type="bibr">22</xref>]. In 2006, Salmi et al. demonstrated that the detection of anti-tTGA2 deposits in the mucosa seems to be rather specific for CD and might be helpful in predicting the evolution to more severe histological damage [<xref rid="B23" ref-type="bibr">23</xref>]. The same data have been discussed in a recent review and, in the same way, have been considered as &#x0201c;markers of existing early disease&#x0201d; [<xref rid="B24" ref-type="bibr">24</xref>].</p><p>tTGA2 deposits were observed by Tosco et al. [<xref rid="B25" ref-type="bibr">25</xref>] following a patchy distribution with areas of clear positivity and areas with absent signal, as already described in mucosal damage of active CD [<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B13" ref-type="bibr">13</xref>]; however, these deposits can also be found only in bulb duodenal biopsies [<xref rid="B26" ref-type="bibr">26</xref>]. In 2017, an Italian study demonstrated that in at-risk infants for CD, detection of mucosal deposits of anti-tTG2 IgA resulted in 88.3% positive predictive value [<xref rid="B22" ref-type="bibr">22</xref>]. The prevalence of <italic>&#x003b3;&#x003b4;</italic> T-cell has also been suggested as a histological biomarker of CD. In fact, an increase in intraepithelial lymphocytes at the villus tip and a high <italic>&#x003b3;&#x003b4;</italic>+ intraepithelial cell count can be considered good predictors of CD in patient with PCD, as described by two different studies from Finland [<xref rid="B27" ref-type="bibr">27</xref>, <xref rid="B28" ref-type="bibr">28</xref>]. Some authors suggest that high density of <italic>&#x003b3;&#x003b4;</italic> T-cell receptor-bearing intraepithelial lymphocytes (IELs) can be a prerequisite for developing CD in patients with no morphological abnormality, yet carrying the susceptibility genes; however, despite an increased density of <italic>&#x003b3;&#x003b4;</italic> T-cell in potential CD, these findings cannot be considered pathognomonic for celiac disease [<xref rid="B29" ref-type="bibr">29</xref>, <xref rid="B30" ref-type="bibr">30</xref>]. It has been hypothesized that in PCD, the intestinal mucosa is maintained architecturally normal by an increased enterocyte proliferation, which will end up in a reduced enterocyte maturity and will thus lead to reduced absorptive capacity of the small bowel [<xref rid="B31" ref-type="bibr">31</xref>]. In the same year, another study demonstrated how T-cells seem to be activated and differentiating toward a Th1 pattern, as suggested by high levels of interleukin-2 (IL-2), interferon-<italic>&#x003b3;</italic> (IFN-<italic>&#x003b3;</italic>), and TGF-<italic>&#x003b2;</italic> transcription factor. The same study showed an increased density of CD4+CD25+Foxp3+ T regulatory cells, which exert suppressive effect not impaired by IL-15 in potential CD [<xref rid="B32" ref-type="bibr">32</xref>]. A recent paper from Borrelli et al. in PCD patients showed reduced expression and increased upregulation in the presence of specific stimuli of interleukin-21 (IL-21), an important cytokine regulating innate and adaptive immune response, differently from active CD. In this study, PCD density of IL-21-producing cells in the lamina propria was found to correlate with serum titer of tTGA2, suggesting a lack of ability of IL-21 to enhance and maintain chronic inflammation in early phases of disease in active or potential CD [<xref rid="B33" ref-type="bibr">33</xref>]. In active CD, the overexpression of IL-21 is likely to play a crucial role in the activation of cytotoxic T-cells leading to epithelial cell death and mucosal destruction [<xref rid="B34" ref-type="bibr">34</xref>]. Aside from immunological controversies, an overlapping metabolomic signature was found for PCD and active disease, suggesting that common functional-biochemical stigmata might call for the same dietary treatment [<xref rid="B35" ref-type="bibr">35</xref>].</p></sec><sec id="sec3"><title>3. To Treat or Not to Treat?</title><p>The therapeutic management of PCD patients represents the main challenge. The only accepted treatment for CD is gluten-free diet (GFD), but the treatment for potential celiac disease still remains unclear. Likewise, there is no clear consensus in the PCD follow-up [<xref rid="B36" ref-type="bibr">36</xref>]. The natural history of PCD, both in adults [<xref rid="B7" ref-type="bibr">7</xref>] and children [<xref rid="B25" ref-type="bibr">25</xref>], is not sufficient to recommend GFD in any patient. Recently, Auricchio et al. [<xref rid="B37" ref-type="bibr">37</xref>] developed a model to predict the evolution to villous atrophy in PCD. They suggested GFD when symptoms of CD can be clearly detected, even without a mucosal damage. This approach aims at reducing symptoms and antibody titers (tTGA2 and EMA), as well as healing minimal alterations in intestinal mucosa [<xref rid="B1" ref-type="bibr">1</xref>]. Conversely, the use of GFD in asymptomatic patients is still debated. In 2009 and 2010, two studies from Finland showed that both adults [<xref rid="B38" ref-type="bibr">38</xref>] and children [<xref rid="B39" ref-type="bibr">39</xref>] with PCD obtained a clinical response to GFD regardless of the presence of small-bowel lesions. According to these studies, the authors suggested to start the dietary treatment as early as possible since treatment would result in reduced risks of delayed puberty and gynecological issues, while avoiding effects on bone mineralization, dental enamel development, and growth. Conversely, in a recent review, Itzlinger et al. considered GFD as inappropriate treatment in asymptomatic patients with PCD [<xref rid="B40" ref-type="bibr">40</xref>].</p><p>Diverging results emerged from Mandile's work, in which only 54% of PCD symptomatic patients have a positive clinical response during the first 12 months of GFD. However, the authors speculated about irritable bowel syndrome as a significant confounding factor in these patients [<xref rid="B41" ref-type="bibr">41</xref>]. In 2014, Auricchio et al. demonstrated that a considerable proportion of PCD patients usually had a fluctuation or decrease of antibody levels, while in those with persistently positive anti-TG2 under a free diet, the mucosal damage was not detectable in 66% of cases until 9 years of follow-up [<xref rid="B42" ref-type="bibr">42</xref>]. In 2019, Lionetti et al. reached similar conclusions: in PCD children on free diet, the risk of progression to overt CD is trivial [<xref rid="B43" ref-type="bibr">43</xref>].</p><p>Previously, Tosco et al. demonstrated that approximately 33% of asymptomatic children with PCD would develop villous atrophy after 3 years without prescribing a GFD [<xref rid="B25" ref-type="bibr">25</xref>]. The authors suggested that most children with potential celiac disease remain healthy and for these reason only symptomatic children would start GFD.</p><p>In 2012, a decision tree for asymptomatic children with tTGA values lower than 11-fold the upper limit normal was proposed [<xref rid="B44" ref-type="bibr">44</xref>]. Symptomless children with a family history of CD and positive CD markers could initially remain on normal free diet, particularly in the case of modest tTGA titer increase. Biopsies should be recommended after a persistent antibody positivity for at least 3-6 months. In 2016, another group indicated that asymptomatic patients can be monitored for the development of new symptoms and/or substantial increase in serum tTGA2 antibodies [<xref rid="B45" ref-type="bibr">45</xref>]. These studies are summarized in <xref rid="tab2" ref-type="table">Table 2</xref> and <xref ref-type="fig" rid="fig2">Figure 2</xref>.</p><p>In conclusion, the presence of symptoms in both adults and children should be considered as the main determinant to prescribe a GFD in potential celiac disease. It is important to remember that all symptoms have to be considered important for the beginning of a GFD. There is no difference in the decision tree, in fact, if patient has gastrointestinal (diarrhea, constipation, abdominal pain) or extraintestinal manifestation (anemia, osteoporosis, migraine), as suggested by Popp and Maki in a recent review too [<xref rid="B24" ref-type="bibr">24</xref>]. As the timing of flattening is totally unpredictable, asymptomatic patients with PCD should undergo a comprehensive follow-up in order to detect early symptoms and promptly start a GFD. A conclusive algorithm is proposed in <xref ref-type="fig" rid="fig3">Figure 3</xref> with the aim to provide valuable information in the management of this challenging condition.</p><p>Further research is necessary in order to establish the optimal frequency of testing the antibodies and clinical evaluation for PCD patients (both adults and children) continuing after initial evaluations on gluten-containing diet. Dietary habits and gluten intake during clinical evaluation should be routinely checked during clinical evaluation, as following a diagnosis of PCD, the patient or his family could decrease the amount of gluten, resulting in false negative serology and fluctuating antibodies.</p></sec></body><back><sec sec-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare that there is no conflict of interest regarding the publication of this paper.</p></sec><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Husby</surname><given-names>S.</given-names></name><etal/></person-group><article-title>European Society for Pediatric Gastroenterology, Hepatology, and Nutrition guidelines for the diagnosis of coeliac disease</article-title><source><italic toggle="yes">Journal of Pediatric Gastroenterology and Nutrition</italic></source><year>2012</year><volume>54</volume><issue>1</issue><fpage>136</fpage><lpage>160</lpage><pub-id pub-id-type="pmid">22197856</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ludvigsson</surname><given-names>J. F.</given-names></name><name><surname>Leffler</surname><given-names>D. A.</given-names></name><name><surname>Bai</surname><given-names>J. C.</given-names></name><etal/></person-group><article-title>The Oslo definitions for coeliac disease and related terms</article-title><source><italic toggle="yes">Gut</italic></source><year>2013</year><volume>62</volume><issue>1</issue><fpage>43</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2011-301346</pub-id><pub-id pub-id-type="other">2-s2.0-84871135111</pub-id><pub-id pub-id-type="pmid">22345659</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferguson</surname><given-names>A.</given-names></name><name><surname>Arranz</surname><given-names>E.</given-names></name><name><surname>O'Mahony</surname><given-names>S.</given-names></name></person-group><article-title>Clinical and pathological spectrum of coeliac disease--active, silent, latent, potential</article-title><source><italic toggle="yes">Gut</italic></source><year>1993</year><volume>34</volume><issue>2</issue><fpage>150</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.1136/gut.34.2.150</pub-id><pub-id pub-id-type="other">2-s2.0-0027469446</pub-id><pub-id pub-id-type="pmid">8432463</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ludvigsson</surname><given-names>J. F.</given-names></name><etal/></person-group><article-title>Screening for celiac disease in the general population and in high-risk groups</article-title><source><italic toggle="yes">United European Gastroenterology Journal</italic></source><year>2015</year><volume>3</volume><issue>2</issue><fpage>106</fpage><lpage>120</lpage><pub-id pub-id-type="pmid">25922671</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonamico</surname><given-names>M.</given-names></name><name><surname>Nenna</surname><given-names>R.</given-names></name><name><surname>Montuori</surname><given-names>M.</given-names></name><etal/></person-group><article-title>First salivary screening of celiac disease by detection of anti-transglutaminase autoantibody radioimmunoassay in 5000 Italian primary schoolchildren</article-title><source><italic toggle="yes">Journal of Pediatric Gastroenterology and Nutrition</italic></source><year>2011</year><volume>52</volume><issue>1</issue><fpage>17</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1097/MPG.0b013e3181e6f2d0</pub-id><pub-id pub-id-type="other">2-s2.0-78650951601</pub-id><pub-id pub-id-type="pmid">21057330</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Catassi</surname><given-names>C.</given-names></name><etal/></person-group><article-title>The coeliac iceberg in Italy. A multicentre antigliadin antibodies screening for coeliac disease in school-age subjects</article-title><source><italic toggle="yes">Acta Paediatrica. Supplement</italic></source><year>1996</year><volume>412</volume><fpage>29</fpage><lpage>35</lpage></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Volta</surname><given-names>U.</given-names></name><etal/></person-group><article-title>Features and progression of potential celiac disease in adults</article-title><source><italic toggle="yes">Clin Gastroenterol Hepatol</italic></source><year>2016</year><volume>14</volume><issue>5</issue><fpage>686</fpage><lpage>93 e1</lpage><pub-id pub-id-type="pmid">26538207</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biagi</surname><given-names>F.</given-names></name><name><surname>Bianchi</surname><given-names>P. I.</given-names></name><name><surname>Vattiato</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Influence of HLA-DQ2 and DQ8 on severity in celiac disease</article-title><source><italic toggle="yes">Journal of Clinical Gastroenterology</italic></source><year>2012</year><volume>46</volume><issue>1</issue><fpage>46</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1097/MCG.0b013e318221077e</pub-id><pub-id pub-id-type="other">2-s2.0-84856468670</pub-id><pub-id pub-id-type="pmid">21694611</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sperandeo</surname><given-names>M. P.</given-names></name><name><surname>Tosco</surname><given-names>A.</given-names></name><name><surname>Izzo</surname><given-names>V.</given-names></name><etal/></person-group><article-title>Potential celiac patients: a model of celiac disease pathogenesis</article-title><source><italic toggle="yes">PLoS One</italic></source><year>2011</year><volume>6</volume><issue>7, article e21281</issue><pub-id pub-id-type="doi">10.1371/journal.pone.0021281</pub-id><pub-id pub-id-type="other">2-s2.0-79960105676</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ravelli</surname><given-names>A.</given-names></name><name><surname>Villanacci</surname><given-names>V.</given-names></name><name><surname>Monfredini</surname><given-names>C.</given-names></name><name><surname>Martinazzi</surname><given-names>S.</given-names></name><name><surname>Grassi</surname><given-names>V.</given-names></name><name><surname>Manenti</surname><given-names>S.</given-names></name></person-group><article-title>How patchy is patchy villous atrophy?: distribution pattern of histological lesions in the duodenum of children with celiac disease</article-title><source><italic toggle="yes">The American Journal of Gastroenterology</italic></source><year>2010</year><volume>105</volume><issue>9</issue><fpage>2103</fpage><lpage>2110</lpage><pub-id pub-id-type="doi">10.1038/ajg.2010.153</pub-id><pub-id pub-id-type="other">2-s2.0-77956344086</pub-id><pub-id pub-id-type="pmid">20372112</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonamico</surname><given-names>M.</given-names></name><name><surname>Mariani</surname><given-names>P.</given-names></name><name><surname>Thanasi</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Patchy villous atrophy of the duodenum in childhood celiac disease</article-title><source><italic toggle="yes">Journal of Pediatric Gastroenterology and Nutrition</italic></source><year>2004</year><volume>38</volume><issue>2</issue><fpage>204</fpage><lpage>207</lpage><pub-id pub-id-type="doi">10.1097/00005176-200402000-00019</pub-id><pub-id pub-id-type="other">2-s2.0-3442898364</pub-id><pub-id pub-id-type="pmid">14734885</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonamico</surname><given-names>M.</given-names></name><name><surname>Thanasi</surname><given-names>E.</given-names></name><name><surname>Mariani</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Duodenal bulb biopsies in celiac disease: a multicenter study</article-title><source><italic toggle="yes">Journal of Pediatric Gastroenterology and Nutrition</italic></source><year>2008</year><volume>47</volume><issue>5</issue><fpage>618</fpage><lpage>622</lpage><pub-id pub-id-type="doi">10.1097/MPG.0b013e3181677d6e</pub-id><pub-id pub-id-type="other">2-s2.0-59849085332</pub-id><pub-id pub-id-type="pmid">18979585</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valitutti</surname><given-names>F.</given-names></name><name><surname>di Nardo</surname><given-names>G.</given-names></name><name><surname>Barbato</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Mapping histologic patchiness of celiac disease by push enteroscopy</article-title><source><italic toggle="yes">Gastrointestinal Endoscopy</italic></source><year>2014</year><volume>79</volume><issue>1</issue><fpage>95</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1016/j.gie.2013.06.012</pub-id><pub-id pub-id-type="other">2-s2.0-84890567123</pub-id><pub-id pub-id-type="pmid">23886355</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ravelli</surname><given-names>A.</given-names></name><name><surname>Villanacci</surname><given-names>V.</given-names></name></person-group><article-title>Tricks of the trade: how to avoid histological pitfalls in celiac disease</article-title><source><italic toggle="yes">Pathology, Research and Practice</italic></source><year>2012</year><volume>208</volume><issue>4</issue><fpage>197</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1016/j.prp.2012.01.008</pub-id><pub-id pub-id-type="other">2-s2.0-84859438963</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Green</surname><given-names>P. H.</given-names></name><name><surname>Jabri</surname><given-names>B.</given-names></name></person-group><article-title>Coeliac disease</article-title><source><italic toggle="yes">Lancet</italic></source><year>2003</year><volume>362</volume><issue>9381</issue><fpage>383</fpage><lpage>391</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(03)14027-5</pub-id><pub-id pub-id-type="other">2-s2.0-0041669320</pub-id><pub-id pub-id-type="pmid">12907013</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andersson</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Influence of the amount of dietary gluten on gastrointestinal morphology and function in dermatitis herpetiformis</article-title><source><italic toggle="yes">Human Nutrition. Clinical Nutrition</italic></source><year>1984</year><volume>38</volume><issue>4</issue><fpage>279</fpage><lpage>285</lpage><pub-id pub-id-type="pmid">6469705</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paparo</surname><given-names>F.</given-names></name><name><surname>Petrone</surname><given-names>E.</given-names></name><name><surname>Tosco</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Clinical, HLA, and small bowel immunohistochemical features of children with positive serum antiendomysium antibodies and architecturally normal small intestinal mucosa</article-title><source><italic toggle="yes">The American Journal of Gastroenterology</italic></source><year>2005</year><volume>100</volume><issue>10</issue><fpage>2294</fpage><lpage>2298</lpage><pub-id pub-id-type="doi">10.1111/j.1572-0241.2005.41134.x</pub-id><pub-id pub-id-type="other">2-s2.0-27744494077</pub-id><pub-id pub-id-type="pmid">16181383</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marzari</surname><given-names>R.</given-names></name><name><surname>Sblattero</surname><given-names>D.</given-names></name><name><surname>Florian</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Molecular dissection of the tissue transglutaminase autoantibody response in celiac disease</article-title><source><italic toggle="yes">Journal of Immunology</italic></source><year>2001</year><volume>166</volume><issue>6</issue><fpage>4170</fpage><lpage>4176</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.166.6.4170</pub-id><pub-id pub-id-type="other">2-s2.0-0035869574</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaukinen</surname><given-names>K.</given-names></name><name><surname>Per&#x000e4;aho</surname><given-names>M.</given-names></name><name><surname>Collin</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Small-bowel mucosal transglutaminase 2-specific IgA deposits in coeliac disease without villous atrophy: a prospective and randomized clinical study</article-title><source><italic toggle="yes">Scandinavian Journal of Gastroenterology</italic></source><year>2005</year><volume>40</volume><issue>5</issue><fpage>564</fpage><lpage>572</lpage><pub-id pub-id-type="doi">10.1080/00365520510023422</pub-id><pub-id pub-id-type="other">2-s2.0-21044456731</pub-id><pub-id pub-id-type="pmid">16036509</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Korponay-Szabo</surname><given-names>I. R.</given-names></name><etal/></person-group><article-title>In vivo targeting of intestinal and extraintestinal transglutaminase 2 by coeliac autoantibodies</article-title><source><italic toggle="yes">Gut</italic></source><year>2004</year><volume>53</volume><issue>5</issue><fpage>641</fpage><lpage>648</lpage><pub-id pub-id-type="doi">10.1136/gut.2003.024836</pub-id><pub-id pub-id-type="other">2-s2.0-2342426804</pub-id><pub-id pub-id-type="pmid">15082580</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koskinen</surname><given-names>O.</given-names></name><etal/></person-group><article-title>Usefulness of small-bowel mucosal transglutaminase-2 specific autoantibody deposits in the diagnosis and follow-up of celiac disease</article-title><source><italic toggle="yes">Journal of Clinical Gastroenterology</italic></source><year>2010</year><volume>44</volume><issue>7</issue><fpage>483</fpage><lpage>488</lpage><pub-id pub-id-type="pmid">19779364</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borrelli</surname><given-names>M.</given-names></name><name><surname>Maglio</surname><given-names>M.</given-names></name><name><surname>Korponay-Szab&#x000f3;</surname><given-names>I. R.</given-names></name><etal/></person-group><article-title>Intestinal anti-transglutaminase 2 immunoglobulin A deposits in children at risk for coeliac disease (CD): data from the prevent CD study</article-title><source><italic toggle="yes">Clinical and Experimental Immunology</italic></source><year>2018</year><volume>191</volume><issue>3</issue><fpage>311</fpage><lpage>317</lpage><pub-id pub-id-type="doi">10.1111/cei.13078</pub-id><pub-id pub-id-type="other">2-s2.0-85036560949</pub-id><pub-id pub-id-type="pmid">29114847</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salmi</surname><given-names>T. T.</given-names></name><etal/></person-group><article-title>Immunoglobulin A autoantibodies against transglutaminase 2 in the small intestinal mucosa predict forthcoming coeliac disease</article-title><source><italic toggle="yes">Alimentary Pharmacology &#x00026; Therapeutics</italic></source><year>2006</year><volume>24</volume><issue>3</issue><fpage>541</fpage><lpage>552</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2036.2006.02997.x</pub-id><pub-id pub-id-type="other">2-s2.0-33745905005</pub-id><?supplied-pmid 16886921?><pub-id pub-id-type="pmid">16886921</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Popp</surname><given-names>A.</given-names></name><name><surname>Maki</surname><given-names>M.</given-names></name></person-group><article-title>Gluten-induced extra-intestinal manifestations in potential celiac disease-celiac trait</article-title><source><italic toggle="yes">Nutrients</italic></source><year>2019</year><volume>11</volume><issue>2</issue><fpage>p. 320</fpage><pub-id pub-id-type="doi">10.3390/nu11020320</pub-id><pub-id pub-id-type="other">2-s2.0-85061144002</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tosco</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Natural history of potential celiac disease in children</article-title><source><italic toggle="yes">Clin Gastroenterol Hepatol</italic></source><year>2011</year><volume>9</volume><issue>4</issue><fpage>320</fpage><lpage>325</lpage><comment>quiz e36</comment><pub-id pub-id-type="pmid">20851213</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Leo</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Immunohistologic analysis of the duodenal bulb: a new method for celiac disease diagnosis in children</article-title><source><italic toggle="yes">Gastrointestinal Endoscopy</italic></source><year>2018</year><volume>88</volume><issue>3</issue><fpage>521</fpage><lpage>526</lpage><pub-id pub-id-type="doi">10.1016/j.gie.2018.05.014</pub-id><pub-id pub-id-type="other">2-s2.0-85050085130</pub-id><pub-id pub-id-type="pmid">29807020</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jarvinen</surname><given-names>T. T.</given-names></name><etal/></person-group><article-title>Villous tip intraepithelial lymphocytes as markers of early-stage coeliac disease</article-title><source><italic toggle="yes">Scandinavian Journal of Gastroenterology</italic></source><year>2004</year><volume>39</volume><issue>5</issue><fpage>428</fpage><lpage>433</lpage><pub-id pub-id-type="doi">10.1080/00365520310008773</pub-id><pub-id pub-id-type="other">2-s2.0-18144443569</pub-id><pub-id pub-id-type="pmid">15180179</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jarvinen</surname><given-names>T. T.</given-names></name><etal/></person-group><article-title>Intraepithelial lymphocytes in celiac disease</article-title><source><italic toggle="yes">The American Journal of Gastroenterology</italic></source><year>2003</year><volume>98</volume><issue>6</issue><fpage>1332</fpage><lpage>1337</lpage><pub-id pub-id-type="pmid">12818278</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holm</surname><given-names>K.</given-names></name><name><surname>M&#x000e4;ki</surname><given-names>M.</given-names></name><name><surname>Savilahti</surname><given-names>E.</given-names></name><name><surname>Laippala</surname><given-names>P.</given-names></name><name><surname>Lipsanen</surname><given-names>V.</given-names></name><name><surname>Koskimies</surname><given-names>S.</given-names></name></person-group><article-title>Intraepithelial gamma delta T-cell-receptor lymphocytes and genetic susceptibility to coeliac disease</article-title><source><italic toggle="yes">Lancet</italic></source><year>1992</year><volume>339</volume><issue>8808</issue><fpage>1500</fpage><lpage>1503</lpage><pub-id pub-id-type="doi">10.1016/0140-6736(92)91262-7</pub-id><pub-id pub-id-type="other">2-s2.0-0026693967</pub-id><pub-id pub-id-type="pmid">1351185</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iltanen</surname><given-names>S.</given-names></name><name><surname>Holm</surname><given-names>K.</given-names></name><name><surname>Partanen</surname><given-names>J.</given-names></name><name><surname>Laippala</surname><given-names>P.</given-names></name><name><surname>Mauki</surname><given-names>M.</given-names></name></person-group><article-title>Increased density of jejunal gammadelta+ T cells in patients having normal mucosa--marker of operative autoimmune mechanisms?</article-title><source><italic toggle="yes">Autoimmunity</italic></source><year>1999</year><volume>29</volume><issue>3</issue><fpage>179</fpage><lpage>187</lpage><pub-id pub-id-type="doi">10.3109/08916939908998533</pub-id><pub-id pub-id-type="other">2-s2.0-0032939962</pub-id><pub-id pub-id-type="pmid">10433098</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biagi</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Prevalence and natural history of potential celiac disease in adult patients</article-title><source><italic toggle="yes">Scandinavian Journal of Gastroenterology</italic></source><year>2013</year><volume>48</volume><issue>5</issue><fpage>537</fpage><lpage>542</lpage><pub-id pub-id-type="pmid">23506211</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borrelli</surname><given-names>M.</given-names></name><name><surname>Salvati</surname><given-names>V. M.</given-names></name><name><surname>Maglio</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Immunoregulatory pathways are active in the small intestinal mucosa of patients with potential celiac disease</article-title><source><italic toggle="yes">The American Journal of Gastroenterology</italic></source><year>2013</year><volume>108</volume><issue>11</issue><fpage>1775</fpage><lpage>1784</lpage><pub-id pub-id-type="doi">10.1038/ajg.2013.303</pub-id><pub-id pub-id-type="other">2-s2.0-84887234999</pub-id><pub-id pub-id-type="pmid">24060758</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borrelli</surname><given-names>M.</given-names></name><etal/></person-group><article-title>In the intestinal mucosa of children with potential celiac disease IL-21 and IL-17A are less expressed than in the active disease</article-title><source><italic toggle="yes">The American Journal of Gastroenterology</italic></source><year>2016</year><volume>111</volume><issue>1</issue><fpage>134</fpage><lpage>144</lpage><pub-id pub-id-type="pmid">26753888</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strengell</surname><given-names>M.</given-names></name><name><surname>Matikainen</surname><given-names>S.</given-names></name><name><surname>Sir&#x000e9;n</surname><given-names>J.</given-names></name><etal/></person-group><article-title>IL-21 in synergy with IL-15 or IL-18 enhances IFN-gamma production in human NK and T cells</article-title><source><italic toggle="yes">Journal of Immunology</italic></source><year>2003</year><volume>170</volume><issue>11</issue><fpage>5464</fpage><lpage>5469</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.170.11.5464</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernini</surname><given-names>P.</given-names></name><name><surname>Bertini</surname><given-names>I.</given-names></name><name><surname>Calabr&#x000f2;</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Are patients with potential celiac disease really potential? The answer of metabonomics</article-title><source><italic toggle="yes">Journal of Proteome Research</italic></source><year>2011</year><volume>10</volume><issue>2</issue><fpage>714</fpage><lpage>721</lpage><pub-id pub-id-type="doi">10.1021/pr100896s</pub-id><pub-id pub-id-type="other">2-s2.0-79955425273</pub-id><pub-id pub-id-type="pmid">21090607</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valitutti</surname><given-names>F.</given-names></name><name><surname>Trovato</surname><given-names>C. M.</given-names></name><name><surname>Montuori</surname><given-names>M.</given-names></name><name><surname>Cucchiara</surname><given-names>S.</given-names></name></person-group><article-title>Pediatric celiac disease: follow-up in the spotlight</article-title><source><italic toggle="yes">Advances in Nutrition</italic></source><year>2017</year><volume>8</volume><issue>2</issue><fpage>356</fpage><lpage>361</lpage><pub-id pub-id-type="doi">10.3945/an.116.013292</pub-id><pub-id pub-id-type="other">2-s2.0-85020162969</pub-id><pub-id pub-id-type="pmid">28298278</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Auricchio</surname><given-names>R.</given-names></name><name><surname>Mandile</surname><given-names>R.</given-names></name><name><surname>del Vecchio</surname><given-names>M. R.</given-names></name><etal/></person-group><article-title>Progression of celiac disease in children with antibodies against tissue transglutaminase and normal duodenal architecture</article-title><source><italic toggle="yes">Gastroenterology</italic></source><year>2019</year><volume>157</volume><issue>2</issue><fpage>413</fpage><lpage>420.e3</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2019.04.004</pub-id><?supplied-pmid 30978358?><pub-id pub-id-type="pmid">30978358</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurppa</surname><given-names>K.</given-names></name><name><surname>Collin</surname><given-names>P.</given-names></name><name><surname>Viljamaa</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Diagnosing mild enteropathy celiac disease: a randomized, controlled clinical study</article-title><source><italic toggle="yes">Gastroenterology</italic></source><year>2009</year><volume>136</volume><issue>3</issue><fpage>816</fpage><lpage>823</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2008.11.040</pub-id><pub-id pub-id-type="other">2-s2.0-60449097714</pub-id><?supplied-pmid 19111551?><pub-id pub-id-type="pmid">19111551</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurppa</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Celiac disease without villous atrophy in children: a prospective study</article-title><source><italic toggle="yes">J Pediatr</italic></source><year>2010</year><volume>157</volume><issue>3</issue><fpage>373</fpage><lpage>380</lpage><comment>380 e1</comment><pub-id pub-id-type="pmid">20400102</pub-id></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Itzlinger</surname><given-names>A.</given-names></name><name><surname>Branchi</surname><given-names>F.</given-names></name><name><surname>Elli</surname><given-names>L.</given-names></name><name><surname>Schumann</surname><given-names>M.</given-names></name></person-group><article-title>Gluten-free diet in celiac disease-forever and for all?</article-title><source><italic toggle="yes">Nutrients</italic></source><year>2018</year><volume>10</volume><issue>11</issue><fpage>p. 1796</fpage><pub-id pub-id-type="doi">10.3390/nu10111796</pub-id><pub-id pub-id-type="other">2-s2.0-85056707995</pub-id></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mandile</surname><given-names>R.</given-names></name><name><surname>Discepolo</surname><given-names>V.</given-names></name><name><surname>Scapaticci</surname><given-names>S.</given-names></name><etal/></person-group><article-title>The effect of gluten-free diet on clinical symptoms and the intestinal mucosa of patients with potential celiac disease</article-title><source><italic toggle="yes">Journal of Pediatric Gastroenterology and Nutrition</italic></source><year>2018</year><volume>66</volume><issue>4</issue><fpage>654</fpage><lpage>656</lpage><pub-id pub-id-type="doi">10.1097/MPG.0000000000001745</pub-id><pub-id pub-id-type="other">2-s2.0-85044222927</pub-id><pub-id pub-id-type="pmid">28922261</pub-id></element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Auricchio</surname><given-names>R.</given-names></name><name><surname>Tosco</surname><given-names>A.</given-names></name><name><surname>Piccolo</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Potential celiac children: 9-year follow-up on a gluten-containing diet</article-title><source><italic toggle="yes">The American Journal of Gastroenterology</italic></source><year>2014</year><volume>109</volume><issue>6</issue><fpage>913</fpage><lpage>921</lpage><pub-id pub-id-type="doi">10.1038/ajg.2014.77</pub-id><pub-id pub-id-type="other">2-s2.0-84902075510</pub-id><pub-id pub-id-type="pmid">24777149</pub-id></element-citation></ref><ref id="B43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lionetti</surname><given-names>E.</given-names></name><name><surname>Castellaneta</surname><given-names>S.</given-names></name><name><surname>Francavilla</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Long-term outcome of potential celiac disease in genetically at-risk children: the prospective CELIPREV cohort study</article-title><source><italic toggle="yes">Journal of Clinical Medicine</italic></source><year>2019</year><volume>8</volume><issue>2</issue><fpage>p. 186</fpage><pub-id pub-id-type="doi">10.3390/jcm8020186</pub-id><?supplied-pmid 30764503?><pub-id pub-id-type="pmid">30764503</pub-id></element-citation></ref><ref id="B44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lionetti</surname><given-names>E.</given-names></name><name><surname>Castellaneta</surname><given-names>S.</given-names></name><name><surname>Pulvirenti</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Prevalence and natural history of potential celiac disease in at-family-risk infants prospectively investigated from birth</article-title><source><italic toggle="yes">The Journal of Pediatrics</italic></source><year>2012</year><volume>161</volume><issue>5</issue><fpage>908</fpage><lpage>914.e2</lpage><pub-id pub-id-type="doi">10.1016/j.jpeds.2012.05.008</pub-id><pub-id pub-id-type="other">2-s2.0-84867888943</pub-id><pub-id pub-id-type="pmid">22704250</pub-id></element-citation></ref><ref id="B45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silvester</surname><given-names>J. A.</given-names></name><name><surname>Kelly</surname><given-names>C. P.</given-names></name></person-group><article-title>The potential for treatment of potential celiac disease</article-title><source><italic toggle="yes">Clinical Gastroenterology and Hepatology</italic></source><year>2016</year><volume>14</volume><issue>5</issue><fpage>694</fpage><lpage>695</lpage><pub-id pub-id-type="doi">10.1016/j.cgh.2016.01.001</pub-id><pub-id pub-id-type="other">2-s2.0-84959248267</pub-id><?supplied-pmid 26767312?><pub-id pub-id-type="pmid">26767312</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="fig1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>The four most important prognostic factors for villous atrophy in PCD.</p></caption><graphic xlink:href="GRP2019-8974751.001"/></fig><fig id="fig2" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Results of available evidence in support or against GFD in PCD asymptomatic patients.</p></caption><graphic xlink:href="GRP2019-8974751.002"/></fig><fig id="fig3" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Diagnostic algorithm for PCD.</p></caption><graphic xlink:href="GRP2019-8974751.003"/></fig><table-wrap id="tab1" orientation="portrait" position="float"><label>Table 1</label><caption><p>A short history of the most important findings concerning PCD.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Study</th><th align="center" rowspan="1" colspan="1">Year</th><th align="center" rowspan="1" colspan="1">Conclusions</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Holm et al. [<xref rid="B29" ref-type="bibr">29</xref>]</td><td align="center" rowspan="1" colspan="1">1992</td><td align="center" rowspan="1" colspan="1">A healthy person who initially has a normal biopsy, but who also has an increased density of <italic>&#x003b3;&#x003b4;</italic> T-cells, may later develop mucosal atrophy compatible with CD.</td></tr><tr><td align="left" rowspan="1" colspan="1">Iltanen et al. [<xref rid="B30" ref-type="bibr">30</xref>]</td><td align="center" rowspan="1" colspan="1">1999</td><td align="center" rowspan="1" colspan="1">39 of 79 (49%) children with normal jejunal mucosa had an increased density of intraepithelial <italic>&#x003b3;&#x003b4;</italic> T-cells.</td></tr><tr><td align="left" rowspan="1" colspan="1">Jarvinen et al. [<xref rid="B28" ref-type="bibr">28</xref>]</td><td align="center" rowspan="1" colspan="1">2003</td><td align="center" rowspan="1" colspan="1">An increase especially in <italic>&#x003b3;&#x003b4;</italic> T-cells strengthens the probability of CD.</td></tr><tr><td align="left" rowspan="1" colspan="1">Korponay-Szabo et al. [<xref rid="B20" ref-type="bibr">20</xref>]</td><td align="center" rowspan="1" colspan="1">2004</td><td align="center" rowspan="1" colspan="1">TG2-related IgA deposits in the morphologically normal jejunum were predictive of forthcoming overt coeliac disease with villous atrophy.</td></tr><tr><td align="left" rowspan="1" colspan="1">Jarvinen et al. [<xref rid="B27" ref-type="bibr">27</xref>]</td><td align="center" rowspan="1" colspan="1">2004</td><td align="center" rowspan="1" colspan="1">The villous tip intraepithelial lymphocyte count was statistically significantly higher in patients with early-stage coeliac disease than in nonceliac controls (sensitivity, 0.84; specificity, 0.88).</td></tr><tr><td align="left" rowspan="1" colspan="1">Paparo et al. [<xref rid="B17" ref-type="bibr">17</xref>]</td><td align="center" rowspan="1" colspan="1">2005</td><td align="center" rowspan="1" colspan="1">Increased number of lamina CD25+ and/or enhanced expression of ICAM 1 and crypt HLA DR.</td></tr><tr><td align="left" rowspan="1" colspan="1">Salmi et al. [<xref rid="B23" ref-type="bibr">23</xref>]</td><td align="center" rowspan="1" colspan="1">2006</td><td align="center" rowspan="1" colspan="1">Intestinal coeliac autoantibody deposit had a sensitivity and specificity of 93% and 93%, respectively, in detecting subsequent coeliac disease.</td></tr><tr><td align="left" rowspan="1" colspan="1">Koskinen et al. [<xref rid="B21" ref-type="bibr">21</xref>]</td><td align="center" rowspan="1" colspan="1">2010</td><td align="center" rowspan="1" colspan="1">Mucosal transglutaminase 2-specific autoantibody deposits proved to be accurate gluten-dependent markers of celiac disease.</td></tr><tr><td align="left" rowspan="1" colspan="1">Tosco et al. [<xref rid="B25" ref-type="bibr">25</xref>]</td><td align="center" rowspan="1" colspan="1">2011</td><td align="center" rowspan="1" colspan="1">In most positive cases a patchy distribution of the deposits was observed with areas of clear positivity and areas with absent signal.</td></tr><tr><td align="left" rowspan="1" colspan="1">Bernini et al. [<xref rid="B35" ref-type="bibr">35</xref>]</td><td align="center" rowspan="1" colspan="1">2011</td><td align="center" rowspan="1" colspan="1">Potential CD largely shares the metabolomic signature of overt CD. Results prove that metabolic alterations may precede the development of small intestinal villous atrophy.</td></tr><tr><td align="left" rowspan="1" colspan="1">Biagi et al. [<xref rid="B31" ref-type="bibr">31</xref>]</td><td align="center" rowspan="1" colspan="1">2013</td><td align="center" rowspan="1" colspan="1">In PCD, the intestinal mucosa is maintained architecturally normal thanks to an increased enterocytic proliferation.</td></tr><tr><td align="left" rowspan="1" colspan="1">Borrelli et al. [<xref rid="B32" ref-type="bibr">32</xref>]</td><td align="center" rowspan="1" colspan="1">2013</td><td align="center" rowspan="1" colspan="1">Potential CD patients show a low grade of inflammation that could likely be due to active regulatory mechanism preventing the progression toward a mucosal damage.</td></tr><tr><td align="left" rowspan="1" colspan="1">Borrelli et al. [<xref rid="B33" ref-type="bibr">33</xref>]</td><td align="center" rowspan="1" colspan="1">2016</td><td align="center" rowspan="1" colspan="1">In potential CD, IL-21 is less expressed than that in active CD.</td></tr><tr><td align="left" rowspan="1" colspan="1">Borrelli et al. [<xref rid="B22" ref-type="bibr">22</xref>]</td><td align="center" rowspan="1" colspan="1">2018</td><td align="center" rowspan="1" colspan="1">In CD, the intestinal deposits of anti-tTG2 are a constant presence and appear very early in the natural history of the disease.</td></tr></tbody></table></table-wrap><table-wrap id="tab2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Results of available evidence in support or against GFD in PCD asymptomatic patients.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Study</th><th align="center" rowspan="1" colspan="1">About GFD</th><th align="center" rowspan="1" colspan="1">Study population</th><th align="center" rowspan="1" colspan="1">Conclusions</th><th align="center" rowspan="1" colspan="1">Limitations</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Tosco et al. [<xref rid="B25" ref-type="bibr">25</xref>]</td><td align="center" rowspan="1" colspan="1">Against GFD</td><td align="center" rowspan="1" colspan="1">106 children</td><td align="center" rowspan="1" colspan="1">33% of incidence of villous atrophy after 3 years in with PCD</td><td align="center" rowspan="1" colspan="1">Unknown number of patients lost at follow-up</td></tr><tr><td align="left" rowspan="1" colspan="1">Lionetti et al. [<xref rid="B44" ref-type="bibr">44</xref>]</td><td align="center" rowspan="1" colspan="1">Against GFD</td><td align="center" rowspan="1" colspan="1">24 asymptomatic children</td><td align="center" rowspan="1" colspan="1">CD markers disappear in most young children with potential CD despite a regular diet</td><td align="center" rowspan="1" colspan="1">Small sample size</td></tr><tr><td align="left" rowspan="1" colspan="1">Silvester et al. [<xref rid="B45" ref-type="bibr">45</xref>]</td><td align="center" rowspan="1" colspan="1">Against GFD</td><td align="center" rowspan="1" colspan="1">
<italic>Review paper</italic>
</td><td align="center" rowspan="1" colspan="1">In the absence of symptoms or villous atrophy, treatment with a GFD does not appear to be necessary in most cases</td><td align="center" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" rowspan="1" colspan="1">Mandile et al. [<xref rid="B41" ref-type="bibr">41</xref>]</td><td align="center" rowspan="1" colspan="1">Against GFD</td><td align="center" rowspan="1" colspan="1">47 children</td><td align="center" rowspan="1" colspan="1">Association between CD and irritable bowel syndrome may be a significant confounding factor</td><td align="center" rowspan="1" colspan="1">Irritable bowel syndrome is overlapping with CD</td></tr><tr><td align="left" rowspan="1" colspan="1">Lionetti et al. [<xref rid="B43" ref-type="bibr">43</xref>]</td><td align="center" rowspan="1" colspan="1">Against GFD</td><td align="center" rowspan="1" colspan="1">23 asymptomatic children</td><td align="center" rowspan="1" colspan="1">Risk of progression to overt CD while on a gluten-containing diet is very low in the long-term.</td><td align="center" rowspan="1" colspan="1">Age of the study group and study design</td></tr><tr><td align="left" rowspan="1" colspan="1">Kurppa et al. [<xref rid="B38" ref-type="bibr">38</xref>]</td><td align="center" rowspan="1" colspan="1">Supports GFD</td><td align="center" rowspan="1" colspan="1">23 adults</td><td align="center" rowspan="1" colspan="1">Patients with endomysial antibodies benefit from a GFD regardless of the degree of enteropathy.</td><td align="center" rowspan="1" colspan="1">Marsh II included in study population</td></tr><tr><td align="left" rowspan="1" colspan="1">Kurppa et al. [<xref rid="B39" ref-type="bibr">39</xref>]</td><td align="center" rowspan="1" colspan="1">Supports GFD</td><td align="center" rowspan="1" colspan="1">17 children</td><td align="center" rowspan="1" colspan="1">Children benefit from early treatment despite normal mucosal structure</td><td align="center" rowspan="1" colspan="1">Small sample size</td></tr></tbody></table></table-wrap></floats-group></article>